Literature DB >> 15469934

Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively.

Lubing Gu1, Ningxi Zhu, Harry W Findley, William G Woods, Muxiang Zhou.   

Abstract

IKKalpha, a subunit of IkBalpha kinase (IKK) complex, has an important role in the activation of nuclear factor-kB (NF-kB), a key regulator of normal and tumor cell proliferation, apoptosis, and response to chemotherapy. However, little is known about the transcriptional regulation of the IKKalpha gene itself. The present study revealed that the transcriptional induction of the IKKalpha gene is positively regulated by binding ETS-1, the protein product of the ETS-1 proto-oncogene. Furthermore, ETS-1 mediated activation of IKKalpha is negatively regulated by p53 binding to ETS-1. By analyzing the genomic DNA sequence, we identified the putative IKKalpha promoter sequence in the 5'-flanking untranslated region of the IKKalpha gene. Transfection of EU-4, an acute lymphoblastic leukemia (ALL) cell line, with plasmids containing the IKKalpha 5'-untranslated region sequence upstream of the luciferase reporter showed that this region possessed major promoter activity. Induction or enforced overexpression of p53 represses IKKalpha mRNA and protein expression as well as IKKalpha promoter activity. Deletion and mutation analyses as well as chromatin immunoprecipitation and electrophoretic mobility shift assay indicated that ETS-1 binds to the core IKKalpha promoter and strongly induces its activity. Although p53 does not directly bind to the IKKalpha promoter, it physically interacts with ETS-1 and specifically inhibits ETS-1-induced IKKalpha promoter activity. These results suggest that the proximal 5'-flanking region of the IKKalpha gene contains a functional promoter reciprocally regulated by p53 and ETS-1. Furthermore, loss of p53-mediated control over ETS-1-dependent transactivation of IKKalpha may represent a novel pathway for the constitutive activation of NF-kB-mediated gene expression and therapy resistance in cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15469934     DOI: 10.1074/jbc.M407915200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Mutant p53 cooperates with ETS2 to promote etoposide resistance.

Authors:  Phi M Do; Lakshman Varanasi; Songqing Fan; Chunyang Li; Iwona Kubacka; Virginia Newman; Krishna Chauhan; Silvano Rakeem Daniels; Maurizio Boccetta; Michael R Garrett; Runzhao Li; Luis A Martinez
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

Review 2.  Current position of TNF-α in melanomagenesis.

Authors:  Iuliana Nenu; Diana Tudor; Adriana Gabriela Filip; Ioana Baldea
Journal:  Tumour Biol       Date:  2015-08-18

3.  A novel mechanism of crosstalk between the p53 and NFκB pathways: MDM2 binds and inhibits p65RelA.

Authors:  Kristina Heyne; Christine Winter; Fabian Gerten; Christina Schmidt; Klaus Roemer
Journal:  Cell Cycle       Date:  2013-06-28       Impact factor: 4.534

4.  Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.

Authors:  Jinming Yang; Wei-Hua Pan; Gary A Clawson; Ann Richmond
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

5.  Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells.

Authors:  Robert B Shirley; Ismail Kaddour-Djebbar; Dimpu M Patel; Vijayabaskar Lakshmikanthan; Ronald W Lewis; M Vijay Kumar
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

6.  An IKKα-nucleophosmin axis utilizes inflammatory signaling to promote genome integrity.

Authors:  Xiaojun Xia; Shuang Liu; Zuoxiang Xiao; Feng Zhu; Na-Young Song; Ming Zhou; Bigang Liu; Jianjun Shen; Kunio Nagashima; Timothy D Veenstra; Sandra Burkett; Mahesh Datla; Jami Willette-Brown; Haifa Shen; Yinling Hu
Journal:  Cell Rep       Date:  2013-11-27       Impact factor: 9.423

7.  NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.

Authors:  Qingqing Cai; Meifeng Tu; Zijun Y Xu-Monette; Ruifang Sun; Ganiraju C Manyam; Xiaolu Xu; Alexander Tzankov; Eric D Hsi; Michael B Møller; L Jeffrey Medeiros; Chi Young Ok; Ken H Young
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

8.  IKKalpha is required to maintain skin homeostasis and prevent skin cancer.

Authors:  Bigang Liu; Xiaojun Xia; Feng Zhu; Eunmi Park; Steve Carbajal; Kaoru Kiguchi; John DiGiovanni; Susan M Fischer; Yinling Hu
Journal:  Cancer Cell       Date:  2008-09-09       Impact factor: 31.743

Review 9.  NF-kappaB activation in melanoma.

Authors:  Yukiko Ueda; Ann Richmond
Journal:  Pigment Cell Res       Date:  2006-04

Review 10.  p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases.

Authors:  Dana Thomasova; Shrikant R Mulay; Hauke Bruns; Hans-Joachim Anders
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.